ABL Diagnostics Société anonyme, a subsidiary of Advanced Biological Laboratories (ABL) S.A., operates within the industrials sector, specifically under the trading companies and distributors industry. The company is listed on the NYSE Euronext Paris and trades in euros (EUR). As of June 16, 2026, ABL Diagnostics closed at a price of 2.4 EUR, with a 52-week high of 5.75 EUR on July 24, 2025, and a 52-week low of 2.12 EUR on May 7, 2026. The company’s market capitalization stands at 38,566,456 EUR, and it has a price-to-earnings ratio of 43.33.
ABL Diagnostics is renowned for its proprietary molecular biology assays and comprehensive solutions designed for molecular detection via polymerase chain reaction (PCR) and DNA sequencing. The company’s offerings include genotyping through next-generation sequencing (NGS) and Sanger sequencing, targeting pathogens such as the human immunodeficiency virus, SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S/18S RNA. Additionally, the company provides ultragene assays for the viral detection of SARS CoV-2, MonkeyPox, and Clostridium.
The company’s product portfolio extends to microbiological specimen transport and collection kits, which encompass saliva preservation, wastewater collection, and surface collection kits, along with inactivation and preservation solutions. ABL Diagnostics also supplies various instruments and consumables, including DNA/RNA extraction systems, real-time PCR systems, liquid handling robots, NGS library preparation kits, and Sanger sequencing reactions.
In the realm of digital solutions, ABL Diagnostics offers analysis software, data hosting, lab automation, Nadis, and SeqHepB. The company distributes its products directly and through a network of distributors to academic clinical pathology labs, private reference labs, and researchers.
Previously known as Etablissements Fauvet Girel, the company rebranded to ABL Diagnostics Société anonyme in April 2022. Its headquarters are located in Woippy, France. Through its innovative solutions and strategic distribution channels, ABL Diagnostics continues to play a pivotal role in the molecular diagnostics landscape both in France and internationally.
